Programmed Cell Death 1 Ligand 2 Protein
"Programmed Cell Death 1 Ligand 2 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A costimulatory B7 antigen that has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 RECEPTOR. It is closely-related to CD274 antigen; however, its expression is restricted to DENDRITIC CELLS and activated MACROPHAGES.
| Descriptor ID |
D061027
|
| MeSH Number(s) |
D12.776.467.150.800 D12.776.543.095.800 D23.050.301.285.800 D23.529.168.800
|
| Concept/Terms |
Programmed Cell Death 1 Ligand 2 Protein- Programmed Cell Death 1 Ligand 2 Protein
- CD273 Antigen
- Antigen, CD273
- PD-L2 Ligand
- Ligand, PD-L2
- PD L2 Ligand
- B7-DC Ligand
- B7 DC Ligand
- Ligand, B7-DC
- Antigens, CD273
- CD273 Antigens
- B7-DC Antigen
- Antigen, B7-DC
- B7 DC Antigen
|
Below are MeSH descriptors whose meaning is more general than "Programmed Cell Death 1 Ligand 2 Protein".
Below are MeSH descriptors whose meaning is more specific than "Programmed Cell Death 1 Ligand 2 Protein".
This graph shows the total number of publications written about "Programmed Cell Death 1 Ligand 2 Protein" by people in this website by year, and whether "Programmed Cell Death 1 Ligand 2 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2014 | 0 | 1 | 1 |
| 2016 | 0 | 1 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Programmed Cell Death 1 Ligand 2 Protein" by people in Profiles.
-
Wolkow N, Jakobiec FA, Afrogheh AH, Kidd M, Eagle RC, Pai SI, Faquin WC. PD-L1 and PD-L2 Expression Levels Are Low in Primary and Secondary Adenoid Cystic Carcinomas of the Orbit: Therapeutic Implications. Ophthalmic Plast Reconstr Surg. 2020 Sep/Oct; 36(5):444-450.
-
Wolkow N, Jakobiec FA, Afrogheh AH, Eagle RC, Pai SI, Faquin WC. Programmed Cell Death 1 Ligand 1 and Programmed Cell Death 1 Ligand 2 Are Expressed in Conjunctival Invasive Squamous Cell Carcinoma: Therapeutic Implications. Am J Ophthalmol. 2019 04; 200:226-241.
-
Mostafa ME, Abdelkader A, Kuroda N, P?rez-Montiel D, Banerjee A, Hes O, Iczkowski KA. Variation in nuclear size and PD-L2 positivity correlate with aggressive chromophobe renal cell carcinoma. Ann Diagn Pathol. 2018 Jun; 34:31-35.
-
Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study. J Clin Oncol. 2016 08 10; 34(23):2698-704.
-
Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, Rodig SJ, Chapuy B, Ligon AH, Zhu L, Grosso JF, Kim SY, Timmerman JM, Shipp MA, Armand P. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015 Jan 22; 372(4):311-9.